Financial economics

Praxis Precision Medicines Prices Public Offering of Common Stock

Friday, May 14, 2021 - 3:39am

b'CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance, today announced that it has priced an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $18.25 per share.

Key Points: 
  • b'CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance, today announced that it has priced an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $18.25 per share.
  • The gross proceeds to Praxis from the offering are expected to be approximately $91.25 million, before deducting the underwriting discounts and commissions and other offering expenses.
  • Praxis has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock.\nAll shares in the offering are to be sold by Praxis.
  • The public offering is being made by Praxis only by means of a prospectus relating to the offering.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Peloton, Repro Med, and ChemoCentryx and Encourages Investors to Contact the Firm

Friday, May 14, 2021 - 3:00am

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.

Key Points: 
  • Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
  • Additional information about each case can be found at the link provided.\nPeloton provides interactive fitness products such as the Peloton Bike and the Peloton Tread+ and Tread, which include touchscreens that stream live and on-demand classes.
  • is a nationally recognized law firm with offices in New York, California, and South Carolina.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Vera Therapeutics Announces Pricing of Initial Public Offering

Friday, May 14, 2021 - 1:52am

b'SOUTH SAN FRANCISCO, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (\xe2\x80\x9cVera\xe2\x80\x9d), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the pricing of its initial public offering of 4,350,000 shares of its Class A common stock at a price to the public of $11.00 per share.

Key Points: 
  • b'SOUTH SAN FRANCISCO, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (\xe2\x80\x9cVera\xe2\x80\x9d), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the pricing of its initial public offering of 4,350,000 shares of its Class A common stock at a price to the public of $11.00 per share.
  • The gross proceeds to Vera from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $47.85 million.
  • All of the shares are being offered by Vera.
  • This offering is being made only by means of a written prospectus, forming a part of the effective registration statement.

Digital Brands Group, Inc. Announces Pricing of $10.0 Million Initial Public Offering and Nasdaq Listing

Friday, May 14, 2021 - 1:58am

In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 361,445 shares and 361,445 warrants at the public offering price less the underwriting discounts and commissions.

Key Points: 
  • In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 361,445 shares and 361,445 warrants at the public offering price less the underwriting discounts and commissions.
  • Manatt, Phelps & Phillips, LLP represented Digital Brands and Nelson Mullins Riley & Scarborough LLP acted for Kingswood.\nThe Securities and Exchange Commission ("SEC") declared effective a registration statement on Form S-1 (File No.
  • The Company has strategically expanded into an omnichannel brand offering these styles and content not only on-line but at selected wholesale and retail storefronts.
  • No assurance can be given that the offering will be completed on the terms described, or at all.

Fluor Announces Pricing of Upsized Convertible Preferred Stock Offering

Friday, May 14, 2021 - 12:04am

b'Fluor Corporation (NYSE: FLR) (the \xe2\x80\x9cCompany\xe2\x80\x9d or \xe2\x80\x9cFluor\xe2\x80\x9d) announced today that it has priced its previously announced private placement of 525,000 shares of a newly created series of convertible preferred stock, to be designated as Series A 6.50% Cumulative Perpetual Convertible Preferred Stock (the \xe2\x80\x9cPreferred Stock\xe2\x80\x9d).

Key Points: 
  • b'Fluor Corporation (NYSE: FLR) (the \xe2\x80\x9cCompany\xe2\x80\x9d or \xe2\x80\x9cFluor\xe2\x80\x9d) announced today that it has priced its previously announced private placement of 525,000 shares of a newly created series of convertible preferred stock, to be designated as Series A 6.50% Cumulative Perpetual Convertible Preferred Stock (the \xe2\x80\x9cPreferred Stock\xe2\x80\x9d).
  • The Company has also increased the size of the offering to 525,000 shares from the previously announced 450,000 shares and has granted the initial purchasers of the Preferred Stock a 30-day option to purchase up to an additional 75,000 in shares of Preferred Stock.
  • The Company intends to use the net proceeds from this offering to redeem or repay outstanding indebtedness and for general corporate purposes.
  • The offering is expected to close on May 18, 2021, subject to customary closing conditions.\nThe Preferred Stock does not have a maturity date.

SAVE FOODS, INC. ANNOUNCES PRICING OF $12 MILLION PUBLIC OFFERING AND NASDAQ LISTING

Thursday, May 13, 2021 - 10:50pm

Save Foods has granted the underwriter a 45-day option to purchase up to 163,636 additional shares of Common Stock to cover over-allotments, if any, at the public offering price, less the underwriting discounts and commissions.

Key Points: 
  • Save Foods has granted the underwriter a 45-day option to purchase up to 163,636 additional shares of Common Stock to cover over-allotments, if any, at the public offering price, less the underwriting discounts and commissions.
  • The Offering is expected to close May 18, 2021, subject to satisfaction of customary closing conditions.
  • A final prospectus relating to this offering will be filed with the Securities and Exchange Commission.
  • Because such statements deal with future events and are based on Save Foods\xe2\x80\x99 current expectations, they are subject to various risks and uncertainties.

Decibel Therapeutics Reports First Quarter 2021 Financial Results and Corporate Update

Thursday, May 13, 2021 - 10:05pm

In early 2021, we announced encouraging preclinical results on our lead gene therapy program, DB-OTO, for the treatment of people with otoferlin deficiency.

Key Points: 
  • In early 2021, we announced encouraging preclinical results on our lead gene therapy program, DB-OTO, for the treatment of people with otoferlin deficiency.
  • We also established a critical cGMP manufacturing and development relationship with Catalent,\xe2\x80\x9d said Laurence Reid, Ph.D., Chief Executive Officer of Decibel.
  • Additionally, Decibel completed its Initial Public Offering (IPO) of 7,662,000 shares of common stock at a public offering price of $18.00 per share.
  • However, while Decibel may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

Aritzia Announces $91 Million Secondary Offering of Subordinate Voting Shares

Thursday, May 13, 2021 - 9:21pm

Proceeds from the Offering will be paid to the Selling Shareholders and the Company will not receive any proceeds from the Offering.

Key Points: 
  • Proceeds from the Offering will be paid to the Selling Shareholders and the Company will not receive any proceeds from the Offering.
  • The subordinate voting shares represent approximately 0.9% of the outstanding subordinate voting shares and the multiple voting shares represent approximately 100.0% of the outstanding multiple voting shares, in each case, on a non-diluted basis.
  • In addition, Mr. Hill holds 220,913 options to acquire subordinate voting shares (each an \xe2\x80\x9cOption\xe2\x80\x9d).\nFollowing closing of the Offering (assuming no exercise of the over-allotment option), the Hill Entities will hold no subordinate voting shares and 21,937,349 multiple voting shares representing an equity interest of approximately 19.9%, and a voting interest of approximately 71.3%, in each case, on a non-diluted basis.
  • The multiple voting shares will represent approximately 100.0% of the outstanding multiple voting shares.

Eloxx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

Thursday, May 13, 2021 - 9:01pm

b"WALTHAM, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (the \xe2\x80\x9cCompany\xe2\x80\x9d) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it has commenced an underwritten public offering of shares of its common stock.

Key Points: 
  • b"WALTHAM, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (the \xe2\x80\x9cCompany\xe2\x80\x9d) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it has commenced an underwritten public offering of shares of its common stock.
  • In addition, the Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock at the public offering price, less underwriting discounts and commissions.\nB.
  • Riley Securities, Inc. is acting as sole-book running manager for the offering.
  • The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

Monaker Group Announces Proposed Public Offering of Common Stock

Thursday, May 13, 2021 - 9:05pm

b'Sunrise, FL, May 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Monaker Group, Inc. (NASDAQ: MKGI), a technology solutions company focused on building a digital business ecosystem that caters to and ties together digital advertisers, consumers, video gamers and travelers, today announced that it has commenced an underwritten public offering of its common stock.

Key Points: 
  • b'Sunrise, FL, May 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Monaker Group, Inc. (NASDAQ: MKGI), a technology solutions company focused on building a digital business ecosystem that caters to and ties together digital advertisers, consumers, video gamers and travelers, today announced that it has commenced an underwritten public offering of its common stock.
  • All of the shares in the offering are being offered by Monaker.
  • In addition, Monaker expects to grant the underwriters a 45-day option to purchase up to an additional 15% of shares of its common stock on the same terms and conditions.
  • A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering has been filed with the SEC.